| GC33600-10mg |
|
1262751-08-5 |
OVA Peptide (257-264) TFA
|
0 |
C47H75F3N10O15 |
|
|
|
| GC33600-5mg |
|
1262751-08-5 |
OVA Peptide (257-264) TFA
|
0 |
C47H75F3N10O15 |
|
|
|
| GC33600-1mg |
|
1262751-08-5 |
OVA Peptide (257-264) TFA
|
0 |
C47H75F3N10O15 |
|
|
|
| GC33599-5mg |
|
1228078-65-6 |
PAR-4 Agonist Peptide, amide TFA (PAR-4-AP (TFA))
|
0 |
C36H49F3N8O9 |
|
|
|
| GC33599-1mg |
|
1228078-65-6 |
PAR-4 Agonist Peptide, amide TFA (PAR-4-AP (TFA))
|
0 |
C36H49F3N8O9 |
|
|
|
| GC33599-10mg |
|
1228078-65-6 |
PAR-4 Agonist Peptide, amide TFA (PAR-4-AP (TFA))
|
0 |
C36H49F3N8O9 |
|
|
|
| GC33597-5mg |
|
110764-09-5 |
Acetyl Perisesaccharide C
|
0 |
C37H62O18 |
|
|
|
| GC33597-10mM(1mLinDMSO) |
|
110764-09-5 |
Acetyl Perisesaccharide C
|
0 |
C37H62O18 |
|
|
|
| GC33596-1mg |
|
102212-99-7 |
5-BrdUTP sodium salt (5-Bromo-2’-deoxyuridine 5’-triphosphate sodium salt)
|
0 |
C9H14BrN2Na4O14P3 |
|
|
|
| GC33595-5mg |
|
101462-82-2 |
β-CGRP, human (Human β-CGRP)
|
0 |
C162H267N51O48S3 |
|
|
|
| GC33595-1mg |
|
101462-82-2 |
β-CGRP, human (Human β-CGRP)
|
0 |
C162H267N51O48S3 |
|
|
|
| GC33595-500μg |
|
101462-82-2 |
β-CGRP, human (Human β-CGRP)
|
0 |
C162H267N51O48S3 |
|
|
|
| GC33594-5g |
|
71-30-7 |
|
0 |
C4H5N3O |
|
|
|
| GC33594-10mM(1mLinDMSO) |
|
71-30-7 |
|
0 |
C4H5N3O |
|
|
|
| GC33593-5mg |
|
136033-55-1 |
|
0 |
C41H68O14 |
|
|
|
| GC33593-10mM(1mLinDMSO) |
|
136033-55-1 |
|
0 |
C41H68O14 |
|
|
|
| GC33592-1mg |
|
112926-02-0 |
Indo-1 AM (Indo-1 Acetoxymethyl ester)
|
0 |
C47H51N3O22 |
|
|
|
| GC33591-100mg |
|
34994-50-8 |
Resorufin sodium salt (NSC 12097 sodium salt)
|
0 |
C12H6NNaO3 |
|
|
|
| GC33590-1g |
|
78338-22-4 |
Thionin acetate (Thionine acetate)
|
0 |
C14H13N3O2S |
|
|
|
| GC33589-1mg |
|
17817-20-8 |
Fluorescein di(β-D-galactopyranoside) (FDG)
|
0 |
C32H32O15 |
|
|
|
